nodes	percent_of_prediction	percent_of_DWPC	metapath
Diclofenac—CYP2C18—Ifosfamide—testicular cancer	0.0806	0.112	CbGbCtD
Diclofenac—UGT2B7—Epirubicin—testicular cancer	0.0468	0.0648	CbGbCtD
Diclofenac—ABCC1—Dactinomycin—testicular cancer	0.0459	0.0636	CbGbCtD
Diclofenac—SLCO1C1—Methotrexate—testicular cancer	0.0443	0.0614	CbGbCtD
Diclofenac—PTGS1—Ifosfamide—testicular cancer	0.0335	0.0464	CbGbCtD
Diclofenac—ABCC1—Epirubicin—testicular cancer	0.0332	0.046	CbGbCtD
Diclofenac—UGT1A1—Etoposide—testicular cancer	0.0315	0.0436	CbGbCtD
Diclofenac—ABCC1—Vinblastine—testicular cancer	0.0287	0.0398	CbGbCtD
Diclofenac—ABCC1—Etoposide—testicular cancer	0.0259	0.0359	CbGbCtD
Diclofenac—CYP2B6—Ifosfamide—testicular cancer	0.0255	0.0353	CbGbCtD
Diclofenac—SLC22A11—Methotrexate—testicular cancer	0.0229	0.0317	CbGbCtD
Diclofenac—ABCC4—Methotrexate—testicular cancer	0.0213	0.0295	CbGbCtD
Diclofenac—CYP2C8—Ifosfamide—testicular cancer	0.0193	0.0268	CbGbCtD
Diclofenac—PTGS2—Cisplatin—testicular cancer	0.0193	0.0267	CbGbCtD
Diclofenac—PTGS2—Etoposide—testicular cancer	0.0189	0.0262	CbGbCtD
Diclofenac—ABCC1—Doxorubicin—testicular cancer	0.0177	0.0245	CbGbCtD
Diclofenac—ABCC1—Methotrexate—testicular cancer	0.0171	0.0237	CbGbCtD
Diclofenac—CYP2C19—Ifosfamide—testicular cancer	0.0162	0.0224	CbGbCtD
Diclofenac—PTGS1—Etoposide—testicular cancer	0.016	0.0222	CbGbCtD
Diclofenac—CYP2C9—Ifosfamide—testicular cancer	0.0135	0.0187	CbGbCtD
Diclofenac—SLC22A8—Methotrexate—testicular cancer	0.0133	0.0184	CbGbCtD
Diclofenac—CYP2B6—Cisplatin—testicular cancer	0.0124	0.0172	CbGbCtD
Diclofenac—CYP2E1—Etoposide—testicular cancer	0.0123	0.0171	CbGbCtD
Diclofenac—ABCB1—Dactinomycin—testicular cancer	0.0111	0.0153	CbGbCtD
Diclofenac—SLC22A6—Methotrexate—testicular cancer	0.00926	0.0128	CbGbCtD
Diclofenac—CYP2C8—Etoposide—testicular cancer	0.00923	0.0128	CbGbCtD
Diclofenac—CYP2B6—Doxorubicin—testicular cancer	0.00831	0.0115	CbGbCtD
Diclofenac—ALB—Methotrexate—testicular cancer	0.00789	0.0109	CbGbCtD
Diclofenac—CYP3A4—Ifosfamide—testicular cancer	0.00783	0.0109	CbGbCtD
Diclofenac—CYP1A2—Etoposide—testicular cancer	0.00714	0.0099	CbGbCtD
Diclofenac—ABCB1—Vinblastine—testicular cancer	0.00693	0.00961	CbGbCtD
Diclofenac—CYP2C9—Cisplatin—testicular cancer	0.00655	0.00908	CbGbCtD
Diclofenac—ABCB1—Cisplatin—testicular cancer	0.00636	0.00881	CbGbCtD
Diclofenac—ABCB1—Etoposide—testicular cancer	0.00624	0.00866	CbGbCtD
Diclofenac—ABCB1—Doxorubicin—testicular cancer	0.00426	0.0059	CbGbCtD
Diclofenac—CYP3A4—Vinblastine—testicular cancer	0.00415	0.00576	CbGbCtD
Diclofenac—ABCB1—Methotrexate—testicular cancer	0.00413	0.00572	CbGbCtD
Diclofenac—CYP3A4—Etoposide—testicular cancer	0.00374	0.00519	CbGbCtD
Diclofenac—CYP3A4—Doxorubicin—testicular cancer	0.00255	0.00354	CbGbCtD
Diclofenac—CXCR1—lymph node—testicular cancer	0.0021	0.0552	CbGeAlD
Diclofenac—PLA2G2A—seminal vesicle—testicular cancer	0.002	0.0524	CbGeAlD
Diclofenac—ASIC1—female gonad—testicular cancer	0.00195	0.051	CbGeAlD
Diclofenac—KCNQ2—gonad—testicular cancer	0.00175	0.046	CbGeAlD
Diclofenac—ASIC1—testis—testicular cancer	0.00173	0.0453	CbGeAlD
Diclofenac—TTR—embryo—testicular cancer	0.00161	0.0421	CbGeAlD
Diclofenac—KCNQ2—female gonad—testicular cancer	0.00142	0.0374	CbGeAlD
Diclofenac—KCNQ2—testis—testicular cancer	0.00126	0.0331	CbGeAlD
Diclofenac—ASIC1—lymph node—testicular cancer	0.00125	0.0328	CbGeAlD
Diclofenac—PLA2G2A—female gonad—testicular cancer	0.00117	0.0308	CbGeAlD
Diclofenac—CXCL8—female gonad—testicular cancer	0.00116	0.0305	CbGeAlD
Diclofenac—CXCR1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00112	0.0339	CbGpPWpGaD
Diclofenac—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00112	0.0339	CbGpPWpGaD
Diclofenac—PLA2G2A—testis—testicular cancer	0.00104	0.0273	CbGeAlD
Diclofenac—CXCL8—testis—testicular cancer	0.00103	0.027	CbGeAlD
Diclofenac—CXCR1—Differentiation Pathway—KITLG—testicular cancer	0.000992	0.0301	CbGpPWpGaD
Diclofenac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000985	0.0298	CbGpPWpGaD
Diclofenac—ASIC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000962	0.0291	CbGpPWpGaD
Diclofenac—SLCO1C1—testis—testicular cancer	0.000879	0.023	CbGeAlD
Diclofenac—UGT2B7—testis—testicular cancer	0.000876	0.023	CbGeAlD
Diclofenac—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000854	0.0259	CbGpPWpGaD
Diclofenac—ALOX5—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000821	0.0248	CbGpPWpGaD
Diclofenac—SCN4A—testis—testicular cancer	0.000807	0.0212	CbGeAlD
Diclofenac—ALOX5—female gonad—testicular cancer	0.000802	0.021	CbGeAlD
Diclofenac—ABCC1—seminal vesicle—testicular cancer	0.000794	0.0208	CbGeAlD
Diclofenac—TTR—testis—testicular cancer	0.000785	0.0206	CbGeAlD
Diclofenac—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000782	0.0237	CbGpPWpGaD
Diclofenac—SLCO1C1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000775	0.0235	CbGpPWpGaD
Diclofenac—PLA2G2A—lymph node—testicular cancer	0.000754	0.0198	CbGeAlD
Diclofenac—CXCR1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000752	0.0228	CbGpPWpGaD
Diclofenac—CXCL8—lymph node—testicular cancer	0.000746	0.0196	CbGeAlD
Diclofenac—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000713	0.0216	CbGpPWpGaD
Diclofenac—ALOX5—testis—testicular cancer	0.000712	0.0187	CbGeAlD
Diclofenac—CXCR1—Differentiation Pathway—KIT—testicular cancer	0.000677	0.0205	CbGpPWpGaD
Diclofenac—ABCC4—Ectoderm Differentiation—TFAP2C—testicular cancer	0.000675	0.0204	CbGpPWpGaD
Diclofenac—CXCL8—Syndecan-3-mediated signaling events—FGFR3—testicular cancer	0.000645	0.0195	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—PRDM14—testicular cancer	0.000638	0.0193	CbGpPWpGaD
Diclofenac—KCNQ3—Developmental Biology—PRDM14—testicular cancer	0.000638	0.0193	CbGpPWpGaD
Diclofenac—SLCO1C1—lymph node—testicular cancer	0.000637	0.0167	CbGeAlD
Diclofenac—UGT2B7—NRF2 pathway—SLC2A6—testicular cancer	0.000628	0.019	CbGpPWpGaD
Diclofenac—ABCC4—NRF2 pathway—SLC2A6—testicular cancer	0.00059	0.0179	CbGpPWpGaD
Diclofenac—CXCR1—GPCR ligand binding—INSL3—testicular cancer	0.000573	0.0173	CbGpPWpGaD
Diclofenac—CYP2E1—seminal vesicle—testicular cancer	0.000569	0.0149	CbGeAlD
Diclofenac—PTGS2—embryo—testicular cancer	0.000558	0.0146	CbGeAlD
Diclofenac—PTGS1—seminal vesicle—testicular cancer	0.000548	0.0144	CbGeAlD
Diclofenac—ABCC4—female gonad—testicular cancer	0.000547	0.0143	CbGeAlD
Diclofenac—PTGS2—seminal vesicle—testicular cancer	0.000524	0.0138	CbGeAlD
Diclofenac—ALOX5—lymph node—testicular cancer	0.000516	0.0135	CbGeAlD
Diclofenac—UGT1A1—NRF2 pathway—SLC2A6—testicular cancer	0.00051	0.0155	CbGpPWpGaD
Diclofenac—SLC22A11—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000509	0.0154	CbGpPWpGaD
Diclofenac—CXCL8—Peptide ligand-binding receptors—INSL3—testicular cancer	0.000506	0.0153	CbGpPWpGaD
Diclofenac—ALB—testis—testicular cancer	0.000501	0.0131	CbGeAlD
Diclofenac—ABCC4—testis—testicular cancer	0.000485	0.0127	CbGeAlD
Diclofenac—SCN4A—Developmental Biology—PRDM14—testicular cancer	0.000483	0.0146	CbGpPWpGaD
Diclofenac—TTR—Amyloids—H2AFZ—testicular cancer	0.000482	0.0146	CbGpPWpGaD
Diclofenac—CXCL8—Bladder Cancer—FGFR3—testicular cancer	0.000472	0.0143	CbGpPWpGaD
Diclofenac—ABCC1—female gonad—testicular cancer	0.000466	0.0122	CbGeAlD
Diclofenac—CYP2B6—gonad—testicular cancer	0.000438	0.0115	CbGeAlD
Diclofenac—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000421	0.0127	CbGpPWpGaD
Diclofenac—CXCL8—Syndecan-2-mediated signaling events—FGFR3—testicular cancer	0.000419	0.0127	CbGpPWpGaD
Diclofenac—ABCC1—testis—testicular cancer	0.000414	0.0109	CbGeAlD
Diclofenac—SLCO1C1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000394	0.0119	CbGpPWpGaD
Diclofenac—SLC22A8—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000388	0.0118	CbGpPWpGaD
Diclofenac—CYP1A1—female gonad—testicular cancer	0.000367	0.00962	CbGeAlD
Diclofenac—ALB—lymph node—testicular cancer	0.000363	0.00953	CbGeAlD
Diclofenac—PTGS1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000356	0.0108	CbGpPWpGaD
Diclofenac—CYP2C8—testis—testicular cancer	0.000352	0.00924	CbGeAlD
Diclofenac—ABCC4—lymph node—testicular cancer	0.000352	0.00922	CbGeAlD
Diclofenac—ABCB1—embryo—testicular cancer	0.000345	0.00906	CbGeAlD
Diclofenac—UGT2B7—Phase II conjugation—HPGDS—testicular cancer	0.000342	0.0103	CbGpPWpGaD
Diclofenac—CXCL8—Syndecan-2-mediated signaling events—MMP2—testicular cancer	0.000341	0.0103	CbGpPWpGaD
Diclofenac—CXCL8—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000339	0.0103	CbGpPWpGaD
Diclofenac—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—testicular cancer	0.000334	0.0101	CbGpPWpGaD
Diclofenac—ABCB1—seminal vesicle—testicular cancer	0.000324	0.00851	CbGeAlD
Diclofenac—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000324	0.00981	CbGpPWpGaD
Diclofenac—CXCR1—GPCR downstream signaling—INSL3—testicular cancer	0.000324	0.0098	CbGpPWpGaD
Diclofenac—PTGS1—female gonad—testicular cancer	0.000322	0.00845	CbGeAlD
Diclofenac—CYP2B6—testis—testicular cancer	0.000316	0.00829	CbGeAlD
Diclofenac—PTGS2—female gonad—testicular cancer	0.000308	0.00807	CbGeAlD
Diclofenac—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000302	0.00914	CbGpPWpGaD
Diclofenac—ABCC1—lymph node—testicular cancer	0.0003	0.00787	CbGeAlD
Diclofenac—CYP2E1—testis—testicular cancer	0.000297	0.00778	CbGeAlD
Diclofenac—CXCR1—Signaling by GPCR—INSL3—testicular cancer	0.000294	0.0089	CbGpPWpGaD
Diclofenac—PTGS1—testis—testicular cancer	0.000286	0.00749	CbGeAlD
Diclofenac—PTGS2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000282	0.00855	CbGpPWpGaD
Diclofenac—UGT1A1—Phase II conjugation—HPGDS—testicular cancer	0.000278	0.00841	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000268	0.00812	CbGpPWpGaD
Diclofenac—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—H2AFZ—testicular cancer	0.00026	0.00788	CbGpPWpGaD
Diclofenac—SLC22A11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000259	0.00783	CbGpPWpGaD
Diclofenac—CXCL8—GPCR ligand binding—INSL3—testicular cancer	0.000258	0.00783	CbGpPWpGaD
Diclofenac—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000251	0.00759	CbGpPWpGaD
Diclofenac—CYP1A1—lymph node—testicular cancer	0.000236	0.00618	CbGeAlD
Diclofenac—ABCB1—gonad—testicular cancer	0.000234	0.00615	CbGeAlD
Diclofenac—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00023	0.00696	CbGpPWpGaD
Diclofenac—CXCL8—ATF-2 transcription factor network—MMP2—testicular cancer	0.00023	0.00695	CbGpPWpGaD
Diclofenac—CXCL8—LPA receptor mediated events—MMP2—testicular cancer	0.000215	0.00651	CbGpPWpGaD
Diclofenac—PTGS1—lymph node—testicular cancer	0.000207	0.00543	CbGeAlD
Diclofenac—CYP2C18—Biological oxidations—HPGDS—testicular cancer	0.000206	0.00622	CbGpPWpGaD
Diclofenac—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000205	0.00621	CbGpPWpGaD
Diclofenac—UGT2B7—Biological oxidations—HPGDS—testicular cancer	0.0002	0.00605	CbGpPWpGaD
Diclofenac—PTGS2—lymph node—testicular cancer	0.000198	0.00519	CbGeAlD
Diclofenac—SLC22A8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000197	0.00597	CbGpPWpGaD
Diclofenac—PTGS2—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000196	0.00592	CbGpPWpGaD
Diclofenac—ABCB1—female gonad—testicular cancer	0.00019	0.00499	CbGeAlD
Diclofenac—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000189	0.00573	CbGpPWpGaD
Diclofenac—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000187	0.00566	CbGpPWpGaD
Diclofenac—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	0.00018	0.00545	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—INSL3—testicular cancer	0.000174	0.00526	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000171	0.00517	CbGpPWpGaD
Diclofenac—ABCB1—testis—testicular cancer	0.000169	0.00443	CbGeAlD
Diclofenac—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000168	0.0051	CbGpPWpGaD
Diclofenac—CXCL8—Cellular Senescence—H2AFZ—testicular cancer	0.000165	0.00499	CbGpPWpGaD
Diclofenac—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000165	0.00498	CbGpPWpGaD
Diclofenac—UGT1A1—Biological oxidations—HPGDS—testicular cancer	0.000162	0.00492	CbGpPWpGaD
Diclofenac—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00016	0.00484	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.00016	0.00484	CbGpPWpGaD
Diclofenac—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000158	0.00477	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—INSL3—testicular cancer	0.000146	0.00442	CbGpPWpGaD
Diclofenac—PTGS2—C-MYB transcription factor network—H2AFZ—testicular cancer	0.000136	0.00413	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—INSL3—testicular cancer	0.000133	0.00402	CbGpPWpGaD
Diclofenac—PTGS1—Biological oxidations—HPGDS—testicular cancer	0.000132	0.00401	CbGpPWpGaD
Diclofenac—PTGS2—C-MYB transcription factor network—KITLG—testicular cancer	0.000125	0.0038	CbGpPWpGaD
Diclofenac—CXCL8—Cellular responses to stress—H2AFZ—testicular cancer	0.000124	0.00377	CbGpPWpGaD
Diclofenac—ABCB1—lymph node—testicular cancer	0.000122	0.00321	CbGeAlD
Diclofenac—ALOX5—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000117	0.00355	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—INSL3—testicular cancer	0.000117	0.00354	CbGpPWpGaD
Diclofenac—KCNQ2—Axon guidance—MMP2—testicular cancer	0.000108	0.00326	CbGpPWpGaD
Diclofenac—KCNQ3—Axon guidance—MMP2—testicular cancer	0.000108	0.00326	CbGpPWpGaD
Diclofenac—TTR—Extracellular matrix organization—MMP2—testicular cancer	0.000103	0.00313	CbGpPWpGaD
Diclofenac—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000102	0.00308	CbGpPWpGaD
Diclofenac—CYP2B6—Biological oxidations—HPGDS—testicular cancer	0.000101	0.00306	CbGpPWpGaD
Diclofenac—CYP2E1—Biological oxidations—HPGDS—testicular cancer	9.9e-05	0.003	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	9.67e-05	0.00293	CbGpPWpGaD
Diclofenac—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	9.34e-05	0.00283	CbGpPWpGaD
Diclofenac—CYP1A1—Biological oxidations—HPGDS—testicular cancer	9.33e-05	0.00283	CbGpPWpGaD
Diclofenac—PTGS2—C-MYB transcription factor network—KIT—testicular cancer	8.56e-05	0.00259	CbGpPWpGaD
Diclofenac—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.56e-05	0.00259	CbGpPWpGaD
Diclofenac—CYP2C8—Biological oxidations—HPGDS—testicular cancer	8.55e-05	0.00259	CbGpPWpGaD
Diclofenac—SCN4A—Axon guidance—MMP2—testicular cancer	8.15e-05	0.00247	CbGpPWpGaD
Diclofenac—Sweating—Doxorubicin—testicular cancer	7.9e-05	0.000381	CcSEcCtD
Diclofenac—Urinary tract disorder—Epirubicin—testicular cancer	7.89e-05	0.000381	CcSEcCtD
Diclofenac—Oedema peripheral—Epirubicin—testicular cancer	7.87e-05	0.00038	CcSEcCtD
Diclofenac—Haematuria—Doxorubicin—testicular cancer	7.85e-05	0.000379	CcSEcCtD
Diclofenac—CXCL8—Signaling Pathways—INSL3—testicular cancer	7.83e-05	0.00237	CbGpPWpGaD
Diclofenac—Urethral disorder—Epirubicin—testicular cancer	7.83e-05	0.000378	CcSEcCtD
Diclofenac—Hepatobiliary disease—Doxorubicin—testicular cancer	7.79e-05	0.000376	CcSEcCtD
Diclofenac—Epistaxis—Doxorubicin—testicular cancer	7.77e-05	0.000375	CcSEcCtD
Diclofenac—Angiopathy—Methotrexate—testicular cancer	7.75e-05	0.000374	CcSEcCtD
Diclofenac—Sinusitis—Doxorubicin—testicular cancer	7.73e-05	0.000373	CcSEcCtD
Diclofenac—Immune system disorder—Methotrexate—testicular cancer	7.71e-05	0.000372	CcSEcCtD
Diclofenac—Visual impairment—Epirubicin—testicular cancer	7.7e-05	0.000371	CcSEcCtD
Diclofenac—Mediastinal disorder—Methotrexate—testicular cancer	7.7e-05	0.000371	CcSEcCtD
Diclofenac—Agranulocytosis—Doxorubicin—testicular cancer	7.69e-05	0.000371	CcSEcCtD
Diclofenac—KCNQ3—Developmental Biology—MMP2—testicular cancer	7.67e-05	0.00232	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—MMP2—testicular cancer	7.67e-05	0.00232	CbGpPWpGaD
Diclofenac—Chills—Methotrexate—testicular cancer	7.66e-05	0.000369	CcSEcCtD
Diclofenac—CYP2C19—Biological oxidations—HPGDS—testicular cancer	7.64e-05	0.00231	CbGpPWpGaD
Diclofenac—Nausea—Ifosfamide—testicular cancer	7.62e-05	0.000367	CcSEcCtD
Diclofenac—Diarrhoea—Cisplatin—testicular cancer	7.57e-05	0.000365	CcSEcCtD
Diclofenac—Erythema multiforme—Epirubicin—testicular cancer	7.56e-05	0.000364	CcSEcCtD
Diclofenac—Alopecia—Methotrexate—testicular cancer	7.55e-05	0.000364	CcSEcCtD
Diclofenac—Bradycardia—Doxorubicin—testicular cancer	7.53e-05	0.000363	CcSEcCtD
Diclofenac—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	7.5e-05	0.00227	CbGpPWpGaD
Diclofenac—Mental disorder—Methotrexate—testicular cancer	7.48e-05	0.000361	CcSEcCtD
Diclofenac—Eye disorder—Epirubicin—testicular cancer	7.47e-05	0.00036	CcSEcCtD
Diclofenac—Hypersensitivity—Etoposide—testicular cancer	7.46e-05	0.00036	CcSEcCtD
Diclofenac—Tinnitus—Epirubicin—testicular cancer	7.45e-05	0.000359	CcSEcCtD
Diclofenac—Erythema—Methotrexate—testicular cancer	7.43e-05	0.000358	CcSEcCtD
Diclofenac—Malnutrition—Methotrexate—testicular cancer	7.43e-05	0.000358	CcSEcCtD
Diclofenac—Haemoglobin—Doxorubicin—testicular cancer	7.43e-05	0.000358	CcSEcCtD
Diclofenac—Cardiac disorder—Epirubicin—testicular cancer	7.42e-05	0.000358	CcSEcCtD
Diclofenac—Flushing—Epirubicin—testicular cancer	7.42e-05	0.000358	CcSEcCtD
Diclofenac—Rhinitis—Doxorubicin—testicular cancer	7.41e-05	0.000357	CcSEcCtD
Diclofenac—Hepatitis—Doxorubicin—testicular cancer	7.4e-05	0.000357	CcSEcCtD
Diclofenac—Haemorrhage—Doxorubicin—testicular cancer	7.4e-05	0.000357	CcSEcCtD
Diclofenac—Hypoaesthesia—Doxorubicin—testicular cancer	7.36e-05	0.000355	CcSEcCtD
Diclofenac—Pharyngitis—Doxorubicin—testicular cancer	7.34e-05	0.000354	CcSEcCtD
Diclofenac—Urinary tract disorder—Doxorubicin—testicular cancer	7.3e-05	0.000352	CcSEcCtD
Diclofenac—Oedema peripheral—Doxorubicin—testicular cancer	7.28e-05	0.000351	CcSEcCtD
Diclofenac—Dysgeusia—Methotrexate—testicular cancer	7.28e-05	0.000351	CcSEcCtD
Diclofenac—Asthenia—Etoposide—testicular cancer	7.27e-05	0.00035	CcSEcCtD
Diclofenac—Angiopathy—Epirubicin—testicular cancer	7.25e-05	0.00035	CcSEcCtD
Diclofenac—Urethral disorder—Doxorubicin—testicular cancer	7.25e-05	0.000349	CcSEcCtD
Diclofenac—Immune system disorder—Epirubicin—testicular cancer	7.22e-05	0.000348	CcSEcCtD
Diclofenac—Mediastinal disorder—Epirubicin—testicular cancer	7.2e-05	0.000347	CcSEcCtD
Diclofenac—Back pain—Methotrexate—testicular cancer	7.19e-05	0.000347	CcSEcCtD
Diclofenac—Chills—Epirubicin—testicular cancer	7.17e-05	0.000346	CcSEcCtD
Diclofenac—Pruritus—Etoposide—testicular cancer	7.17e-05	0.000346	CcSEcCtD
Diclofenac—Arrhythmia—Epirubicin—testicular cancer	7.14e-05	0.000344	CcSEcCtD
Diclofenac—Visual impairment—Doxorubicin—testicular cancer	7.13e-05	0.000344	CcSEcCtD
Diclofenac—PLA2G2A—Metabolism—HPGDS—testicular cancer	7.12e-05	0.00215	CbGpPWpGaD
Diclofenac—Alopecia—Epirubicin—testicular cancer	7.06e-05	0.00034	CcSEcCtD
Diclofenac—Vomiting—Cisplatin—testicular cancer	7.03e-05	0.000339	CcSEcCtD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	7.02e-05	0.00213	CbGpPWpGaD
Diclofenac—Vision blurred—Methotrexate—testicular cancer	7.01e-05	0.000338	CcSEcCtD
Diclofenac—Mental disorder—Epirubicin—testicular cancer	7e-05	0.000338	CcSEcCtD
Diclofenac—Erythema multiforme—Doxorubicin—testicular cancer	6.99e-05	0.000337	CcSEcCtD
Diclofenac—Rash—Cisplatin—testicular cancer	6.97e-05	0.000336	CcSEcCtD
Diclofenac—Dermatitis—Cisplatin—testicular cancer	6.97e-05	0.000336	CcSEcCtD
Diclofenac—CYP2C9—Biological oxidations—HPGDS—testicular cancer	6.96e-05	0.00211	CbGpPWpGaD
Diclofenac—Erythema—Epirubicin—testicular cancer	6.96e-05	0.000335	CcSEcCtD
Diclofenac—Malnutrition—Epirubicin—testicular cancer	6.96e-05	0.000335	CcSEcCtD
Diclofenac—Diarrhoea—Etoposide—testicular cancer	6.93e-05	0.000334	CcSEcCtD
Diclofenac—Eye disorder—Doxorubicin—testicular cancer	6.91e-05	0.000333	CcSEcCtD
Diclofenac—Ill-defined disorder—Methotrexate—testicular cancer	6.9e-05	0.000333	CcSEcCtD
Diclofenac—Tinnitus—Doxorubicin—testicular cancer	6.89e-05	0.000332	CcSEcCtD
Diclofenac—Anaemia—Methotrexate—testicular cancer	6.87e-05	0.000331	CcSEcCtD
Diclofenac—Flushing—Doxorubicin—testicular cancer	6.86e-05	0.000331	CcSEcCtD
Diclofenac—Cardiac disorder—Doxorubicin—testicular cancer	6.86e-05	0.000331	CcSEcCtD
Diclofenac—Flatulence—Epirubicin—testicular cancer	6.86e-05	0.000331	CcSEcCtD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	6.85e-05	0.00208	CbGpPWpGaD
Diclofenac—Tension—Epirubicin—testicular cancer	6.83e-05	0.000329	CcSEcCtD
Diclofenac—Dysgeusia—Epirubicin—testicular cancer	6.81e-05	0.000328	CcSEcCtD
Diclofenac—Nervousness—Epirubicin—testicular cancer	6.76e-05	0.000326	CcSEcCtD
Diclofenac—Back pain—Epirubicin—testicular cancer	6.73e-05	0.000324	CcSEcCtD
Diclofenac—Angiopathy—Doxorubicin—testicular cancer	6.71e-05	0.000323	CcSEcCtD
Diclofenac—Malaise—Methotrexate—testicular cancer	6.7e-05	0.000323	CcSEcCtD
Diclofenac—Dizziness—Etoposide—testicular cancer	6.7e-05	0.000323	CcSEcCtD
Diclofenac—Muscle spasms—Epirubicin—testicular cancer	6.69e-05	0.000322	CcSEcCtD
Diclofenac—Immune system disorder—Doxorubicin—testicular cancer	6.68e-05	0.000322	CcSEcCtD
Diclofenac—Vertigo—Methotrexate—testicular cancer	6.68e-05	0.000322	CcSEcCtD
Diclofenac—Mediastinal disorder—Doxorubicin—testicular cancer	6.66e-05	0.000321	CcSEcCtD
Diclofenac—Leukopenia—Methotrexate—testicular cancer	6.65e-05	0.000321	CcSEcCtD
Diclofenac—Chills—Doxorubicin—testicular cancer	6.64e-05	0.00032	CcSEcCtD
Diclofenac—Arrhythmia—Doxorubicin—testicular cancer	6.61e-05	0.000318	CcSEcCtD
Diclofenac—Nausea—Cisplatin—testicular cancer	6.57e-05	0.000317	CcSEcCtD
Diclofenac—Vision blurred—Epirubicin—testicular cancer	6.56e-05	0.000316	CcSEcCtD
Diclofenac—Alopecia—Doxorubicin—testicular cancer	6.53e-05	0.000315	CcSEcCtD
Diclofenac—Cough—Methotrexate—testicular cancer	6.49e-05	0.000313	CcSEcCtD
Diclofenac—Mental disorder—Doxorubicin—testicular cancer	6.48e-05	0.000312	CcSEcCtD
Diclofenac—Ill-defined disorder—Epirubicin—testicular cancer	6.46e-05	0.000311	CcSEcCtD
Diclofenac—Convulsion—Methotrexate—testicular cancer	6.44e-05	0.000311	CcSEcCtD
Diclofenac—Vomiting—Etoposide—testicular cancer	6.44e-05	0.000311	CcSEcCtD
Diclofenac—Erythema—Doxorubicin—testicular cancer	6.44e-05	0.00031	CcSEcCtD
Diclofenac—Malnutrition—Doxorubicin—testicular cancer	6.44e-05	0.00031	CcSEcCtD
Diclofenac—Anaemia—Epirubicin—testicular cancer	6.43e-05	0.00031	CcSEcCtD
Diclofenac—Agitation—Epirubicin—testicular cancer	6.39e-05	0.000308	CcSEcCtD
Diclofenac—Rash—Etoposide—testicular cancer	6.39e-05	0.000308	CcSEcCtD
Diclofenac—Dermatitis—Etoposide—testicular cancer	6.38e-05	0.000308	CcSEcCtD
Diclofenac—Headache—Etoposide—testicular cancer	6.35e-05	0.000306	CcSEcCtD
Diclofenac—Flatulence—Doxorubicin—testicular cancer	6.34e-05	0.000306	CcSEcCtD
Diclofenac—Arthralgia—Methotrexate—testicular cancer	6.33e-05	0.000305	CcSEcCtD
Diclofenac—Chest pain—Methotrexate—testicular cancer	6.33e-05	0.000305	CcSEcCtD
Diclofenac—Myalgia—Methotrexate—testicular cancer	6.33e-05	0.000305	CcSEcCtD
Diclofenac—Tension—Doxorubicin—testicular cancer	6.32e-05	0.000305	CcSEcCtD
Diclofenac—Dysgeusia—Doxorubicin—testicular cancer	6.3e-05	0.000304	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	6.29e-05	0.000303	CcSEcCtD
Diclofenac—Malaise—Epirubicin—testicular cancer	6.27e-05	0.000302	CcSEcCtD
Diclofenac—Discomfort—Methotrexate—testicular cancer	6.25e-05	0.000301	CcSEcCtD
Diclofenac—Nervousness—Doxorubicin—testicular cancer	6.25e-05	0.000301	CcSEcCtD
Diclofenac—Vertigo—Epirubicin—testicular cancer	6.25e-05	0.000301	CcSEcCtD
Diclofenac—Syncope—Epirubicin—testicular cancer	6.24e-05	0.000301	CcSEcCtD
Diclofenac—Leukopenia—Epirubicin—testicular cancer	6.23e-05	0.0003	CcSEcCtD
Diclofenac—Back pain—Doxorubicin—testicular cancer	6.23e-05	0.0003	CcSEcCtD
Diclofenac—Muscle spasms—Doxorubicin—testicular cancer	6.19e-05	0.000298	CcSEcCtD
Diclofenac—Palpitations—Epirubicin—testicular cancer	6.15e-05	0.000296	CcSEcCtD
Diclofenac—Confusional state—Methotrexate—testicular cancer	6.12e-05	0.000295	CcSEcCtD
Diclofenac—Loss of consciousness—Epirubicin—testicular cancer	6.11e-05	0.000295	CcSEcCtD
Diclofenac—Cough—Epirubicin—testicular cancer	6.07e-05	0.000293	CcSEcCtD
Diclofenac—Anaphylactic shock—Methotrexate—testicular cancer	6.07e-05	0.000293	CcSEcCtD
Diclofenac—Vision blurred—Doxorubicin—testicular cancer	6.07e-05	0.000292	CcSEcCtD
Diclofenac—Convulsion—Epirubicin—testicular cancer	6.03e-05	0.000291	CcSEcCtD
Diclofenac—Infection—Methotrexate—testicular cancer	6.03e-05	0.000291	CcSEcCtD
Diclofenac—Nausea—Etoposide—testicular cancer	6.02e-05	0.00029	CcSEcCtD
Diclofenac—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.02e-05	0.00182	CbGpPWpGaD
Diclofenac—Hypertension—Epirubicin—testicular cancer	6.01e-05	0.00029	CcSEcCtD
Diclofenac—Ill-defined disorder—Doxorubicin—testicular cancer	5.97e-05	0.000288	CcSEcCtD
Diclofenac—Nervous system disorder—Methotrexate—testicular cancer	5.95e-05	0.000287	CcSEcCtD
Diclofenac—Anaemia—Doxorubicin—testicular cancer	5.95e-05	0.000287	CcSEcCtD
Diclofenac—CYP1A2—Biological oxidations—HPGDS—testicular cancer	5.95e-05	0.0018	CbGpPWpGaD
Diclofenac—Thrombocytopenia—Methotrexate—testicular cancer	5.94e-05	0.000286	CcSEcCtD
Diclofenac—Chest pain—Epirubicin—testicular cancer	5.92e-05	0.000286	CcSEcCtD
Diclofenac—Arthralgia—Epirubicin—testicular cancer	5.92e-05	0.000286	CcSEcCtD
Diclofenac—Myalgia—Epirubicin—testicular cancer	5.92e-05	0.000286	CcSEcCtD
Diclofenac—Agitation—Doxorubicin—testicular cancer	5.92e-05	0.000285	CcSEcCtD
Diclofenac—Anxiety—Epirubicin—testicular cancer	5.9e-05	0.000285	CcSEcCtD
Diclofenac—Skin disorder—Methotrexate—testicular cancer	5.89e-05	0.000284	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	5.88e-05	0.000284	CcSEcCtD
Diclofenac—Hyperhidrosis—Methotrexate—testicular cancer	5.87e-05	0.000283	CcSEcCtD
Diclofenac—Discomfort—Epirubicin—testicular cancer	5.85e-05	0.000282	CcSEcCtD
Diclofenac—SCN4A—Developmental Biology—MMP2—testicular cancer	5.81e-05	0.00176	CbGpPWpGaD
Diclofenac—Malaise—Doxorubicin—testicular cancer	5.81e-05	0.00028	CcSEcCtD
Diclofenac—Dry mouth—Epirubicin—testicular cancer	5.79e-05	0.000279	CcSEcCtD
Diclofenac—Vertigo—Doxorubicin—testicular cancer	5.78e-05	0.000279	CcSEcCtD
Diclofenac—Anorexia—Methotrexate—testicular cancer	5.78e-05	0.000279	CcSEcCtD
Diclofenac—Syncope—Doxorubicin—testicular cancer	5.77e-05	0.000278	CcSEcCtD
Diclofenac—Leukopenia—Doxorubicin—testicular cancer	5.76e-05	0.000278	CcSEcCtD
Diclofenac—Confusional state—Epirubicin—testicular cancer	5.73e-05	0.000276	CcSEcCtD
Diclofenac—Palpitations—Doxorubicin—testicular cancer	5.69e-05	0.000274	CcSEcCtD
Diclofenac—Anaphylactic shock—Epirubicin—testicular cancer	5.68e-05	0.000274	CcSEcCtD
Diclofenac—Oedema—Epirubicin—testicular cancer	5.68e-05	0.000274	CcSEcCtD
Diclofenac—Hypotension—Methotrexate—testicular cancer	5.67e-05	0.000273	CcSEcCtD
Diclofenac—Loss of consciousness—Doxorubicin—testicular cancer	5.66e-05	0.000273	CcSEcCtD
Diclofenac—Infection—Epirubicin—testicular cancer	5.64e-05	0.000272	CcSEcCtD
Diclofenac—Cough—Doxorubicin—testicular cancer	5.62e-05	0.000271	CcSEcCtD
Diclofenac—Shock—Epirubicin—testicular cancer	5.59e-05	0.000269	CcSEcCtD
Diclofenac—Convulsion—Doxorubicin—testicular cancer	5.58e-05	0.000269	CcSEcCtD
Diclofenac—Nervous system disorder—Epirubicin—testicular cancer	5.57e-05	0.000268	CcSEcCtD
Diclofenac—Thrombocytopenia—Epirubicin—testicular cancer	5.56e-05	0.000268	CcSEcCtD
Diclofenac—Hypertension—Doxorubicin—testicular cancer	5.56e-05	0.000268	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—H2AFZ—testicular cancer	5.56e-05	0.00168	CbGpPWpGaD
Diclofenac—Tachycardia—Epirubicin—testicular cancer	5.54e-05	0.000267	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Methotrexate—testicular cancer	5.53e-05	0.000267	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—STK11—testicular cancer	5.52e-05	0.00167	CbGpPWpGaD
Diclofenac—Skin disorder—Epirubicin—testicular cancer	5.52e-05	0.000266	CcSEcCtD
Diclofenac—Hyperhidrosis—Epirubicin—testicular cancer	5.49e-05	0.000265	CcSEcCtD
Diclofenac—Insomnia—Methotrexate—testicular cancer	5.49e-05	0.000265	CcSEcCtD
Diclofenac—Chest pain—Doxorubicin—testicular cancer	5.48e-05	0.000264	CcSEcCtD
Diclofenac—Arthralgia—Doxorubicin—testicular cancer	5.48e-05	0.000264	CcSEcCtD
Diclofenac—Myalgia—Doxorubicin—testicular cancer	5.48e-05	0.000264	CcSEcCtD
Diclofenac—Anxiety—Doxorubicin—testicular cancer	5.46e-05	0.000263	CcSEcCtD
Diclofenac—Paraesthesia—Methotrexate—testicular cancer	5.45e-05	0.000263	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	5.44e-05	0.000262	CcSEcCtD
Diclofenac—Discomfort—Doxorubicin—testicular cancer	5.41e-05	0.000261	CcSEcCtD
Diclofenac—Anorexia—Epirubicin—testicular cancer	5.41e-05	0.000261	CcSEcCtD
Diclofenac—Dyspnoea—Methotrexate—testicular cancer	5.41e-05	0.000261	CcSEcCtD
Diclofenac—Somnolence—Methotrexate—testicular cancer	5.39e-05	0.00026	CcSEcCtD
Diclofenac—Dry mouth—Doxorubicin—testicular cancer	5.36e-05	0.000258	CcSEcCtD
Diclofenac—Dyspepsia—Methotrexate—testicular cancer	5.34e-05	0.000257	CcSEcCtD
Diclofenac—TTR—Disease—H2AFZ—testicular cancer	5.34e-05	0.00162	CbGpPWpGaD
Diclofenac—Hypotension—Epirubicin—testicular cancer	5.31e-05	0.000256	CcSEcCtD
Diclofenac—Confusional state—Doxorubicin—testicular cancer	5.3e-05	0.000255	CcSEcCtD
Diclofenac—Decreased appetite—Methotrexate—testicular cancer	5.27e-05	0.000254	CcSEcCtD
Diclofenac—Oedema—Doxorubicin—testicular cancer	5.25e-05	0.000253	CcSEcCtD
Diclofenac—Anaphylactic shock—Doxorubicin—testicular cancer	5.25e-05	0.000253	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Methotrexate—testicular cancer	5.24e-05	0.000253	CcSEcCtD
Diclofenac—Fatigue—Methotrexate—testicular cancer	5.23e-05	0.000252	CcSEcCtD
Diclofenac—ALOX5—Metabolism—HPGDS—testicular cancer	5.22e-05	0.00158	CbGpPWpGaD
Diclofenac—Infection—Doxorubicin—testicular cancer	5.22e-05	0.000252	CcSEcCtD
Diclofenac—Pain—Methotrexate—testicular cancer	5.19e-05	0.00025	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Epirubicin—testicular cancer	5.17e-05	0.000249	CcSEcCtD
Diclofenac—PLA2G2A—Metabolism—STK11—testicular cancer	5.17e-05	0.00157	CbGpPWpGaD
Diclofenac—Shock—Doxorubicin—testicular cancer	5.17e-05	0.000249	CcSEcCtD
Diclofenac—Nervous system disorder—Doxorubicin—testicular cancer	5.15e-05	0.000248	CcSEcCtD
Diclofenac—Thrombocytopenia—Doxorubicin—testicular cancer	5.14e-05	0.000248	CcSEcCtD
Diclofenac—Insomnia—Epirubicin—testicular cancer	5.14e-05	0.000248	CcSEcCtD
Diclofenac—Tachycardia—Doxorubicin—testicular cancer	5.13e-05	0.000247	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—KITLG—testicular cancer	5.11e-05	0.00155	CbGpPWpGaD
Diclofenac—Skin disorder—Doxorubicin—testicular cancer	5.1e-05	0.000246	CcSEcCtD
Diclofenac—Paraesthesia—Epirubicin—testicular cancer	5.1e-05	0.000246	CcSEcCtD
Diclofenac—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.09e-05	0.00154	CbGpPWpGaD
Diclofenac—Hyperhidrosis—Doxorubicin—testicular cancer	5.08e-05	0.000245	CcSEcCtD
Diclofenac—Dyspnoea—Epirubicin—testicular cancer	5.06e-05	0.000244	CcSEcCtD
Diclofenac—Somnolence—Epirubicin—testicular cancer	5.05e-05	0.000243	CcSEcCtD
Diclofenac—Anorexia—Doxorubicin—testicular cancer	5.01e-05	0.000241	CcSEcCtD
Diclofenac—Feeling abnormal—Methotrexate—testicular cancer	5e-05	0.000241	CcSEcCtD
Diclofenac—Dyspepsia—Epirubicin—testicular cancer	5e-05	0.000241	CcSEcCtD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	4.98e-05	0.00151	CbGpPWpGaD
Diclofenac—Gastrointestinal pain—Methotrexate—testicular cancer	4.96e-05	0.000239	CcSEcCtD
Diclofenac—Decreased appetite—Epirubicin—testicular cancer	4.94e-05	0.000238	CcSEcCtD
Diclofenac—TTR—Disease—KITLG—testicular cancer	4.91e-05	0.00149	CbGpPWpGaD
Diclofenac—Hypotension—Doxorubicin—testicular cancer	4.91e-05	0.000237	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Epirubicin—testicular cancer	4.9e-05	0.000236	CcSEcCtD
Diclofenac—Fatigue—Epirubicin—testicular cancer	4.9e-05	0.000236	CcSEcCtD
Diclofenac—Pain—Epirubicin—testicular cancer	4.86e-05	0.000234	CcSEcCtD
Diclofenac—Constipation—Epirubicin—testicular cancer	4.86e-05	0.000234	CcSEcCtD
Diclofenac—Urticaria—Methotrexate—testicular cancer	4.82e-05	0.000232	CcSEcCtD
Diclofenac—Body temperature increased—Methotrexate—testicular cancer	4.8e-05	0.000231	CcSEcCtD
Diclofenac—Abdominal pain—Methotrexate—testicular cancer	4.8e-05	0.000231	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Doxorubicin—testicular cancer	4.79e-05	0.000231	CcSEcCtD
Diclofenac—Insomnia—Doxorubicin—testicular cancer	4.75e-05	0.000229	CcSEcCtD
Diclofenac—Paraesthesia—Doxorubicin—testicular cancer	4.72e-05	0.000227	CcSEcCtD
Diclofenac—Dyspnoea—Doxorubicin—testicular cancer	4.68e-05	0.000226	CcSEcCtD
Diclofenac—Feeling abnormal—Epirubicin—testicular cancer	4.68e-05	0.000226	CcSEcCtD
Diclofenac—Somnolence—Doxorubicin—testicular cancer	4.67e-05	0.000225	CcSEcCtD
Diclofenac—Gastrointestinal pain—Epirubicin—testicular cancer	4.64e-05	0.000224	CcSEcCtD
Diclofenac—Dyspepsia—Doxorubicin—testicular cancer	4.62e-05	0.000223	CcSEcCtD
Diclofenac—CYP3A4—Biological oxidations—HPGDS—testicular cancer	4.59e-05	0.00139	CbGpPWpGaD
Diclofenac—Decreased appetite—Doxorubicin—testicular cancer	4.57e-05	0.00022	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Doxorubicin—testicular cancer	4.54e-05	0.000219	CcSEcCtD
Diclofenac—Fatigue—Doxorubicin—testicular cancer	4.53e-05	0.000218	CcSEcCtD
Diclofenac—Urticaria—Epirubicin—testicular cancer	4.51e-05	0.000217	CcSEcCtD
Diclofenac—Constipation—Doxorubicin—testicular cancer	4.49e-05	0.000217	CcSEcCtD
Diclofenac—Pain—Doxorubicin—testicular cancer	4.49e-05	0.000217	CcSEcCtD
Diclofenac—Body temperature increased—Epirubicin—testicular cancer	4.49e-05	0.000216	CcSEcCtD
Diclofenac—Abdominal pain—Epirubicin—testicular cancer	4.49e-05	0.000216	CcSEcCtD
Diclofenac—Hypersensitivity—Methotrexate—testicular cancer	4.47e-05	0.000216	CcSEcCtD
Diclofenac—Asthenia—Methotrexate—testicular cancer	4.35e-05	0.00021	CcSEcCtD
Diclofenac—Feeling abnormal—Doxorubicin—testicular cancer	4.33e-05	0.000209	CcSEcCtD
Diclofenac—Gastrointestinal pain—Doxorubicin—testicular cancer	4.3e-05	0.000207	CcSEcCtD
Diclofenac—Pruritus—Methotrexate—testicular cancer	4.29e-05	0.000207	CcSEcCtD
Diclofenac—Hypersensitivity—Epirubicin—testicular cancer	4.18e-05	0.000202	CcSEcCtD
Diclofenac—Urticaria—Doxorubicin—testicular cancer	4.17e-05	0.000201	CcSEcCtD
Diclofenac—Abdominal pain—Doxorubicin—testicular cancer	4.15e-05	0.0002	CcSEcCtD
Diclofenac—Body temperature increased—Doxorubicin—testicular cancer	4.15e-05	0.0002	CcSEcCtD
Diclofenac—Diarrhoea—Methotrexate—testicular cancer	4.15e-05	0.0002	CcSEcCtD
Diclofenac—Asthenia—Epirubicin—testicular cancer	4.07e-05	0.000196	CcSEcCtD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.04e-05	0.00122	CbGpPWpGaD
Diclofenac—Pruritus—Epirubicin—testicular cancer	4.02e-05	0.000194	CcSEcCtD
Diclofenac—Dizziness—Methotrexate—testicular cancer	4.01e-05	0.000193	CcSEcCtD
Diclofenac—Diarrhoea—Epirubicin—testicular cancer	3.89e-05	0.000187	CcSEcCtD
Diclofenac—Hypersensitivity—Doxorubicin—testicular cancer	3.87e-05	0.000187	CcSEcCtD
Diclofenac—Vomiting—Methotrexate—testicular cancer	3.86e-05	0.000186	CcSEcCtD
Diclofenac—Rash—Methotrexate—testicular cancer	3.83e-05	0.000184	CcSEcCtD
Diclofenac—Dermatitis—Methotrexate—testicular cancer	3.82e-05	0.000184	CcSEcCtD
Diclofenac—Headache—Methotrexate—testicular cancer	3.8e-05	0.000183	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—FGFR3—testicular cancer	3.8e-05	0.00115	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—STK11—testicular cancer	3.79e-05	0.00115	CbGpPWpGaD
Diclofenac—Asthenia—Doxorubicin—testicular cancer	3.77e-05	0.000182	CcSEcCtD
Diclofenac—Dizziness—Epirubicin—testicular cancer	3.75e-05	0.000181	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—H2AFZ—testicular cancer	3.74e-05	0.00113	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—STK11—testicular cancer	3.72e-05	0.00113	CbGpPWpGaD
Diclofenac—Pruritus—Doxorubicin—testicular cancer	3.72e-05	0.000179	CcSEcCtD
Diclofenac—TTR—Disease—FGFR3—testicular cancer	3.65e-05	0.00111	CbGpPWpGaD
Diclofenac—Vomiting—Epirubicin—testicular cancer	3.61e-05	0.000174	CcSEcCtD
Diclofenac—Nausea—Methotrexate—testicular cancer	3.6e-05	0.000174	CcSEcCtD
Diclofenac—Diarrhoea—Doxorubicin—testicular cancer	3.59e-05	0.000173	CcSEcCtD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.58e-05	0.00108	CbGpPWpGaD
Diclofenac—Rash—Epirubicin—testicular cancer	3.58e-05	0.000173	CcSEcCtD
Diclofenac—Dermatitis—Epirubicin—testicular cancer	3.58e-05	0.000172	CcSEcCtD
Diclofenac—Headache—Epirubicin—testicular cancer	3.56e-05	0.000171	CcSEcCtD
Diclofenac—CYP2C18—Metabolism—HPGDS—testicular cancer	3.51e-05	0.00106	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—KIT—testicular cancer	3.49e-05	0.00106	CbGpPWpGaD
Diclofenac—Dizziness—Doxorubicin—testicular cancer	3.47e-05	0.000167	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—KITLG—testicular cancer	3.44e-05	0.00104	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—HPGDS—testicular cancer	3.42e-05	0.00104	CbGpPWpGaD
Diclofenac—Nausea—Epirubicin—testicular cancer	3.37e-05	0.000163	CcSEcCtD
Diclofenac—TTR—Disease—KIT—testicular cancer	3.35e-05	0.00101	CbGpPWpGaD
Diclofenac—Vomiting—Doxorubicin—testicular cancer	3.34e-05	0.000161	CcSEcCtD
Diclofenac—Rash—Doxorubicin—testicular cancer	3.31e-05	0.00016	CcSEcCtD
Diclofenac—Dermatitis—Doxorubicin—testicular cancer	3.31e-05	0.00016	CcSEcCtD
Diclofenac—Headache—Doxorubicin—testicular cancer	3.29e-05	0.000159	CcSEcCtD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.28e-05	0.000995	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.27e-05	0.000989	CbGpPWpGaD
Diclofenac—CXCL8—Metabolism of proteins—MMP2—testicular cancer	3.24e-05	0.00098	CbGpPWpGaD
Diclofenac—Nausea—Doxorubicin—testicular cancer	3.12e-05	0.00015	CcSEcCtD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.93e-05	0.000888	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—HPGDS—testicular cancer	2.78e-05	0.000841	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—HPGDS—testicular cancer	2.68e-05	0.000811	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.67e-05	0.00081	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—FGFR3—testicular cancer	2.56e-05	0.000774	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—STK11—testicular cancer	2.55e-05	0.000773	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—H2AFZ—testicular cancer	2.51e-05	0.000759	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—STK11—testicular cancer	2.49e-05	0.000755	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—STK11—testicular cancer	2.48e-05	0.000752	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—KIT—testicular cancer	2.35e-05	0.000711	CbGpPWpGaD
Diclofenac—ABCC1—Disease—H2AFZ—testicular cancer	2.34e-05	0.000708	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—KITLG—testicular cancer	2.31e-05	0.000699	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.28e-05	0.000692	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—HPGDS—testicular cancer	2.26e-05	0.000686	CbGpPWpGaD
Diclofenac—ABCC1—Disease—KITLG—testicular cancer	2.15e-05	0.000651	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—STK11—testicular cancer	2.02e-05	0.000611	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—STK11—testicular cancer	1.95e-05	0.000589	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—HPGDS—testicular cancer	1.8e-05	0.000544	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—HPGDS—testicular cancer	1.73e-05	0.000523	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—FGFR3—testicular cancer	1.71e-05	0.000519	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—HPGDS—testicular cancer	1.69e-05	0.000512	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—STK11—testicular cancer	1.65e-05	0.000498	CbGpPWpGaD
Diclofenac—ABCC1—Disease—FGFR3—testicular cancer	1.6e-05	0.000484	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—HPGDS—testicular cancer	1.6e-05	0.000483	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—KIT—testicular cancer	1.57e-05	0.000477	CbGpPWpGaD
Diclofenac—PTGS2—Disease—H2AFZ—testicular cancer	1.57e-05	0.000475	CbGpPWpGaD
Diclofenac—ABCC1—Disease—KIT—testicular cancer	1.47e-05	0.000444	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—HPGDS—testicular cancer	1.46e-05	0.000443	CbGpPWpGaD
Diclofenac—ALB—Metabolism—HPGDS—testicular cancer	1.45e-05	0.00044	CbGpPWpGaD
Diclofenac—PTGS2—Disease—KITLG—testicular cancer	1.44e-05	0.000437	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—STK11—testicular cancer	1.31e-05	0.000396	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—HPGDS—testicular cancer	1.31e-05	0.000395	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—HPGDS—testicular cancer	1.27e-05	0.000386	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—STK11—testicular cancer	1.26e-05	0.00038	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—STK11—testicular cancer	1.23e-05	0.000372	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—HPGDS—testicular cancer	1.19e-05	0.000361	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—STK11—testicular cancer	1.16e-05	0.000351	CbGpPWpGaD
Diclofenac—PTGS2—Disease—FGFR3—testicular cancer	1.07e-05	0.000325	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—STK11—testicular cancer	1.06e-05	0.000322	CbGpPWpGaD
Diclofenac—ALB—Metabolism—STK11—testicular cancer	1.06e-05	0.00032	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—HPGDS—testicular cancer	1.02e-05	0.000308	CbGpPWpGaD
Diclofenac—PTGS2—Disease—KIT—testicular cancer	9.85e-06	0.000298	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—STK11—testicular cancer	9.49e-06	0.000287	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—STK11—testicular cancer	9.26e-06	0.00028	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—STK11—testicular cancer	8.65e-06	0.000262	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—HPGDS—testicular cancer	7.85e-06	0.000238	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—STK11—testicular cancer	7.39e-06	0.000224	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—STK11—testicular cancer	5.71e-06	0.000173	CbGpPWpGaD
